Immunosuppressive therapy and an angiotensin II receptor blocker were initiated; however, remission of nephrotic syndrome was not achieved.One year after the treatment, urinary glucose became negative (0.03 g/dL).Subsequently, an SGLT2 inhibitor was introduced for renal protection, which led to an increase in urinary glucose excretion to 0.43 g/dL, suggesting recovery of SGLT2 function. Conclusion:We report the first case of primary MN associated with loss of SGLT2 expression.The undetectable urinary glucose after therapeutic intervention for MN and the reappearance of glycosuria following SGLT2 inhibitor therapy suggest that SGLT2 expression may be reversible.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.
Ishida et al. (Wed,) studied this question.